[This review was originally posted at the Nieman Journalism Lab Retin A No Rx, on March 23, 2012.]

The agony and the ecstasy of Mike Daisey: The story that dominated this week broke last Friday, when This American Life announced it would retract a January story about abuses in Apple's factories in China. The piece, adapted from a monologue performance by Mike Daisey, turned out to be littered with falsehoods, which were discovered by a reporter for Marketplace and subsequently admitted by Daisey. Order Retin A online c.o.d, (As it turned out, Gawker's Adrian Chen had already been partway down this road, too.) TAL devoted a full episode to the retraction, and the resulting outrage led Daisey to change his show ... but not that much.

Daisey's response was far more defensive than contrite, Retin A dangers. His initial statement contended that his only regret was to let a theatrical monologue air on a journalistic program, Retin A No Rx. A follow-up lamented that people were using this controversy as an excuse to deny the reality of where their gadgets come from. You can also hear his prologue from one of last weekend's shows, as well as a much longer defense of his story (helpfully transcribed here).

Daisey's response — not to mention his lying in the first place — wasn't received well. Real brand Retin A online, J-prof Jay Rosen called it the response of a "master manipulator," and several others objected to his contention that he wasn't bound to a strict definition of truth because he's in theater, not journalism. J-prof Jeff Jarvis said truth is the norm for everyone Retin A No Rx, , and Grist's Scott Rosenberg argued that Daisey drew a bright line between journalism and theater (and journalism and activism) that doesn't exist. Blogger Rachel Joy Larris contended that Daisey was aping the practice of journalism to give his stories a veneer of credibility.

Several commentators delved into the possible reasons for Daisey's fabrications: Reuters' Felix Salmon said that it stemmed from a desire to turn a complicated reality into a simple narrative with clear good guys and bad guys, the New Yorker's Evan Osnos posited that Daisey believed that China was too faraway and exotic to be fact-checked, Retin A mg. Two other bloggers, Matthew Baldwin and Aaron Bady, said Daisey's main problem was his narcissistic need to put himself at the center of his stories, and Arik Hesseldahl of All Things D refuted Daisey's assertion that he was the only one shining a light on these abuses. Order Retin A no prescription, An Economist blogger highlighted the role that Daisey's misguided effort to blame the media for its supposed oversight played in his falsehoods and his defense.

Daisey did have a few defenders—entrepreneur Kevin Slavin, Apple co-founder Steve Wozniak, and columnist Michael Wolff, who argued that journalists' preoccupation with factual diligence neglects the fact that good writing is what audiences value, Retin A No Rx. Additionally, others, included these professors writing at CNN, were worried that Daisey's lies would distract from the larger truth of abuses in Apple's factories in China.

Time's James Poniewozik offered a similar "larger truth" point, fast shipping Retin A, but pinned the blame solely on Daisey — because of his lying, other well-reported accounts of abuses will be tarred by the "larger truth" of Daisey's exposure. Others had different problems with the "larger truth" argument by Daisey and his defenders: Slate's Daniel Engber said Daisey's story wasn't even substantially true, and Gawker's John Cook described the "larger truth" argument as an artful attempt to get around the simple fact that "those things didn't actually happen." And Slate's Jason Zinoman said the "larger truth" has already been reported by numerous outlets; the only thing Daisey added to those stories were precisely the things he made up. Retin A australia, uk, us, usa, So what about This American Life's role in all this. The New York Times' David Carr was relatively sympathetic Retin A No Rx, , contending that no matter what mechanisms are employed, some fabulists will always slip through journalism's cracks. But at the Columbia Journalism Review, Lawrence Pintak pointed out plenty of problems in TAL's fact-checking process, and Poynter's Craig Silverman said it wasn't fact-checking at all. Jay Rosen wondered whether that fact-checking failure was because TAL has fallen too deeply in love with stories, and Poynter's Roy Peter Clark offered a similar indictment: "Ira Glass wanted the story to be true, Retin A dose. He let down his guard – and his audience, who also wanted the story to be true."

Also at Poynter, Steve Myers and Craig Silverman presented some lingering questions about TAL's standards and fact-checking processes, and here at the Lab, Canada, mexico, india, Ken Doctor suggested that the solution isn't to try to erecting higher walls between journalism and everything else, but to acknowledge and disclose the blurring boundaries that come with digital media convergence.

—

Ceding ground in news to the tech Goliaths: Pew's Project for Excellence in Journalism released its annual State of the Media report this week, and its overview lays out the themes pretty well: Mobile media consumption has come of age, a handful of tech giants are taking the lion's share of the economic benefits as they fight to gain jurisdiction over more of our online lives, and the decline of traditional media continues to take its toll, generic Retin A, financially and civically. Jeff Sonderman of Poynter also has a good summary of some of the other findings, especially as media consumption is concerned, Retin A No Rx.

One area that got some attention was on Facebook and Twitter use for news, which found that only 9 percent of American adults get their news often from Facebook and Twitter recommendations. Peter Kafka of All Things D interpreted the findings to mean that even though social media is much further along as a news source than it was just a few years ago, Retin A coupon, it's still on the early-adopter curve.

PaidContent's Staci Kramer pointed out a few other social media findings that make sense — Twitter users are more likely to follow links from news sources and news recommendations from non-news sources, and they're more likely not to know where a news recommendation comes from. And GigaOM's Mathew Ingram saw a larger trend of personalized curation and aggregation, in which platforms like Facebook are becoming major players — and "frenemies" of news orgs.

The Lab's Adrienne LaFrance focused Retin A No Rx, on who's getting the money in this scramble for mobile and digital news dominance, and landed on the tech giants, pointing out that five tech companies (not including Apple and Amazon) received 68 percent of all digital ad revenue last year. She talked to the project's Amy Mitchell about the prospect that one of those companies could swoop in to take over a struggling news org and the idea that "technology leaders might identify news production as a path to omnipresence in consumers’ lives." Poynter's Rick Edmonds looked at the way this is hitting newspapers, about Retin A, warning that they're close the edge of losing a critical mass of advertising revenue.

—

The Times' pay plan tightens up: It's been a year now since the New York Times launched its paid-content plan, and Joe Pompeo of Capital New York detailed its inception and its success: More subscribers than the paper anticipated and the same overall web audience, though slightly lower traffic. Buy Retin A from canada, He also touched on the Times' plans for the paywall going forward, including its attempts to grow internationally and to convert more casual readers to subscribers, partly through tablets.

The Times unveiled the next step in its paywall development the next morning, announcing that it would drop the number of free articles per month before the wall kicks in from 20 to 10. (You can still get Times articles after you hit the wall by finding them through blogs, social media and, to a lesser extent, search.) Peter Kafka of All Things D wondered whether the Times was making the change simply because it could or because it had to, Retin A No Rx.

The Times also announced a total of 454, buy Retin A from mexico,000 digital subscribers, which, as Pompeo reported, is well on its way to the 600, My Retin A experience, 000 to 1 million it may ultimately need to be a success. The Columbia Journalism Review's Ryan Chittum was impressed by the number of subscriptions, but he suggested that the Times might be able to rope in a few more younger readers by tightening the loopholes to its system.

—

Reading roundup: There wasn't a whole lot being discussed in the journalism/tech world this week outside of the Daisey debacle, but there were still a few miscellaneous pieces worth reading:

— Fortune was the latest media outlet to cover Pinterest's meteoric rise, but some real warts are emerging: More attention is being drawn to its copyright problems from people like artist Glendon Mellow and the photographers' group Artists' Bill of Rights. Pinterest has assured that it's addressing copyright issues. MediaShift, meanwhile, showed how j-school profs are using Pinterest in their classes.

— On one side of media utopian/dystopian divide, Sasha Frere-Jones of the New Yorker offered a fine rebuttal to the argument that Twitter inhibits deep thought and serious argument.

— On the other, cultural critic Evgeny Morozov lamented the possible dangers to privacy in automated forms of journalism in a piece at Slate, decrying "our refusal to investigate the social and political consequences of living in a world where reading anonymously becomes a near impossibility."

— Finally, the Lab's Andrew Phelps put together a smart analysis of Gawker's new editorial strategy of alternating "traffic-whoring" with more substantive posts.

Similar posts: Flagyl Cost. Cipro Cost. Bactrim Over The Counter. Online buying Flagyl hcl. Discount Flagyl. Glucophage brand name.
Trackbacks from: Retin A No Rx. Retin A No Rx. Retin A No Rx. Cheap Retin A no rx. Rx free Retin A. Retin A long term.

[This review was originally posted at the Nieman Journalism Lab Purchase Lipitor, on March 18, 2011.]

First reactions to The Times' paid-content plans: Yesterday The New York Times rolled out the online paid-content plans they've been talking about for a little more than a year. You get 20 articles a month for free (besides the ones you get to through Google and social media), and after that it's going to cost you anywhere from $15 to $35 per four weeks, depending on what devices you want to access it on. Print subscribers will get it all for free. (Yup, as the Lab's Josh Benton and Forbes' Jeff Bercovici pointed out, that means there are print plans with online access that are cheaper than the online-only ones.) Subscriptions will sold, Lipitor results, among other places, in Apple's iTunes store. Here's The Times' letter to readers and news article, as well as the Lab's glimpse at the paywall and a good paidContent FAQ.

Now for the reaction and analysis: If you only have time for a few pieces, make them Ken Doctor, Steve Outing, and Felix Salmon, Purchase Lipitor. If you want a quick sampler platter of opinions, you can't do any better than the Lab's roundup of 11 experts' thoughts.

There was no consensus of initial opinion about the plan; many supporters spoke up quickly, including The Times' own media critic, David Carr, purchase Lipitor, and The Daily Beast's Howard Kurtz. Poynter newspaper analyst Rick Edmonds broke down the ways it met all the initial criteria of a sound paywall plan, and British j-prof Paul Bradshaw called it "the most mature, intelligent, and commercially sensible paywall model yet," praising its respect for distribution and online engagement. At The Columbia Journalism Review, Lipitor over the counter, Ryan Chittum said it looked good, and Lauren Kirchner issued a rejoinder to the "information wants to be free" crowd. Purchase Lipitor, The Times' detractors were quick to speak up, too. Media analyst Steve Outing laid out most of the basic objections: The prices are too high, people will turn away when they hit the 20-article limit, and the differentiation by device doesn't make sense. (TechCrunch's Erick Schonfeld harped on the latter point, too.) Reuters' Felix Salmon chimed in by saying that the price point is high enough that a lot of regular readers won't subscribe (meaning the plan won't bring in much revenue anyway), and that the Times is discouraging use of its iPad.

At BoingBoing, Lipitor forum, Cory Doctorow said most users will find the metering system frustrating, leading them to find other ways to read The Times or just not read it at all. Techdirt's Mike Masnick made a similar point, adding that The Times isn't adding any value with the plan. That was tech pioneer Dave Winer's main beef: "They're not offering anything to readers other than the Times' survival, and they're not even explicit about that."

Plenty of commentary didn't fall into either the "pro" or "con" camp, of course, Purchase Lipitor. Here at the Lab, Ken Doctor provided the definitive economic analysis of the plan, breaking down the seven tests it must pass to be successful. Discount Lipitor, Then there was the issue of getting around the paywall (or, as Doctor more accurately called it, the fence): Business Insider told us how to do it via Google, and TechCrunch pontificated on the social media loophole that will develop in addition to the current Google one. Media consultant Steve Yelvington downplayed that factor: "It's not supposed to be a bank vault, people. It's a polite request for payment."

Another obvious next question is whether this could be applied to other news organizations. Purchase Lipitor, Meranda Watling of 10,000 Words compared the plan with those of The Wall Street Journal and Newsday, but Amy Gahran of the Knight Digital Media Center gave other newspapers a stern "don't try this at home."

—

Breaking down an old debate at SXSW: Just as they do every March, geeks descended on Austin, Texas, last weekend for the South by Southwest Interactive Festival, and as usual, there was plenty of journalism-related stuff to chew on, even for those of us who didn't attend. The session that seemed to get the most traction online was NYU professor Jay Rosen's psychological analysis of the tension between bloggers and journalists — which is perhaps a bit surprising for a battle that Rosen himself declared "over" six years ago.

Rosen's whole talk is worth a read, online buy Lipitor without a prescription, but here's the gist of it: For journalists, bloggers are the idealized face of all the ideological and professional stresses they deal with, and for bloggers, the conflict helps keep them on the "outside" of the system, allowing them to maintain their innocence and rhetorical power. Snarkmarket's Matt Thompson and Tim Carmody liveblogged their analysis of the talk, and The Guardian summarized it. Lipitor pics, Michele McLellan of the Knight Digital Media Center ripped blogger-hating journalists for fighting an outdated war, but Melissa Bell of the Washington Post called Rosen's characterization of objectivity misleading.

There were plenty of other panels worth reading about, too, including NYU prof Clay Shirky's timely talk on social media and revolution, in which he said that governments routinely overestimate our access to information and underestimate our access to each other, Purchase Lipitor. (The Guardian had a short summary, and Poynter's Julie Moos put together a blow-by-blow in Storify.)

There were also a couple of panels on the value of gaming, particularly in news, as well as sessions on building trust online, using social media to evade censorship, the future of public media, iPad news apps, is Lipitor safe, and SEO tips from Google and Bing. Poynter's Steve Myers pulled together a dozen journalists for an overview of the conference in terms of building community, and an Economist blogger tied this year's SXSW to last year's with a sharp post questioning the story as the basic unit of journalism.

—

A critical eye on NPR's antagonists: The damage to NPR from James O'Keefe's hidden-camera exposé was already done last week, but the scrutiny of the tape itself didn't begin in earnest until the weekend — kicked off by, of all places, Glenn Beck's website, Lipitor from canada,  The Blaze. (Time's James Poniewozik's breakdown is also worth a read.) The site's skepticism of the video's editing was picked up by NPR media reporter David Folkenflik, who examined the issue in a broadcast report. NPR's spokeswoman called the video Purchase Lipitor, "inappropriately edited," but said the executive in the tape had still made "egregious statements."

Whatever O'Keefe's ethics, Poynter's Steve Myers said, there's plenty he understands about today's media environment that we can learn from: Investigative journalism is in demand, raw media communicates "reality," and soundbites and reducing opponents' logic to absurdities trump context in the online media world.

The change in leadership at NPR prompted others to look at the health and direction of the organization overall: The New York Times' David Carr examined NPR's success in light of the public-funding argument, and Poynter's Mallary Jean Tenore laid out the four biggest challenges for NPR's next CEO. The Lab's Nikki Usher looked overseas for public media comparisons, and The Columbia Journalism Review talked to Jonathan Holmes of the Australian Broadcasting Corporation about the public media situation there.

—

A snapshot of the state of journalism: Pew's Project for Excellence in Journalism released its annual State of the Media report this week, summarizing last year as a good one for journalism. The big headline that most media outlets took away from the study was that for the first time, online news consumption has surpassed newspaper use. There were plenty of other nuggets from the study, though, covering a variety of news media.

The study outlined the state of the newspaper industry, touching on all the major themes from circulation to advertising to digital paid-content efforts, Purchase Lipitor. One of the authors of that part of the study, Poynter's Rick Edmonds, Lipitor overnight,  summarized the trends he found interesting.

It also included a look at the economics of startup community journalism, with discussion of nonprofits, ad-based sites, and the Patch model. (Author Michele McLellan summarized her main points here.) The researchers also reported on a survey on mobile news use, and Amy Gahran of the Knight Digital Media Center and Damon Kiesow of Poynter highlighted some of the opportunities for news organizations in its results.

A couple of other tidbits from the study: Search Engine Land's Vanessa Fox focused on revenue from advertising, subscriptions, Lipitor alternatives, and mobile apps, and j-prof Alfred Hermida pointed out the difference between the news agendas of Twitter, blogs and the mainstream media.

—

Twitter tells developers to hold off: Twitter made waves in the tech world late last week when they posted a note Purchase Lipitor, telling developers not to develop any more Twitter clients, saying they'd like to do it themselves, ostensibly for consistency's sake. (Mashable has a great explanation of the issue.) Most of the initial reaction was not enthusiastic: Salon's Dan Gillmor said the note was a reminder that we need other options for our online platforms that aren't controlled by a single company, and Dave Winer said it reinforces the fact the open web is the best place to develop.

Mathew Ingram of GigaOM and developer Fred Oliveira both urged Twitter to rethink its decision, noting that third-party apps like Tweetdeck and Tweetie spurred much of Twitter's initial growth. Lipitor without prescription, And ReadWriteWeb's Marshall Kirkpatrick saw this as a hint at where Twitter is headed culturally: "If you thought Twitter was a place for outlaws, for free thinkers, for innovators - you need to tuck in your shirt, cut your hair and get a clue."

Others, however, defended Twitter: Social media marketer Jesse Stay said he wishes Twitter had done this a while ago, and developer Rob Diana argued that Twitter has finally given developers a solid sense of direction while still giving them some freedom.

—

Reading roundup: A few notes to digest while your bracket goes up in flames:

— The big news story of the past week has been the earthquake, tsunami and their aftermath in Japan, Lipitor online cod. There wasn't a whole lot written about it from a media perspective, but there were a couple of insightful posts, Purchase Lipitor. Doc Searls looked at coverage and concluded that the web is subsuming TV and radio, and Jeff Jarvis asked for separate Twitter hashtags for breaking news event witnesses.

— A few leftover AOL/Huffington Post items: GigaOM's Mathew Ingram looked at why AOL is desperate for some successful content initiatives, Arianna Huffington talked SEO, TechCrunch broke down the journalism/churnalism tension at AOL, and The New York Times' Bill Keller issued a non-apology followup to his Huffington-bashing essay last week.

— A couple of stray items from the commenting discussion of the last couple of weeks: Via O'Reilly Radar, Effects of Lipitor,  statistics showing the integration of Facebook Comments led to fewer comments at TechCrunch, and a defense of anonymous commenting from Paul O'Flaherty.

— Finally, the Lab has the transcript of an interesting talk Northwestern prof Pablo Boczkowski gave about the gap between what news consumers want and what they get, with a thoughtful response from the Lab's Josh Benton. Enjoy.

Similar posts: Diflucan Cost. Diflucan For Sale. Armour Price. Cipro alternatives. Armour blogs. Diflucan duration.
Trackbacks from: Purchase Lipitor. Purchase Lipitor. Purchase Lipitor. Lipitor results. Lipitor street price. Generic Lipitor.